Aileron Therapeutics prices ~$20M registered direct offering of stock and warrants

Rein Therapeutics, Inc.

4,273,505 shares and accompanying warrants sold at combined $4.68/unit; gross proceeds ~$20M, net ~$17.9M.
Warrants exercisable at $4.68/share for 3 years; callable by Aileron after top-line LTI-03 Phase 1b results if VWAP exceeds exercise price.
Net proceeds to fund LTI-03 Phase 1b trial, working capital; cash runway projected through Q2 2025.
Offering closing on May 3, 2024; Titan Partners Group acted as sole book-runner.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Rein Therapeutics, Inc. entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC valued at combined offering price of $4.68 (effective 2024-05-01).

Action: entry
Agreement: underwriting
Counterparty: Titan Partners Group LLC, a division of American Capital Partners, LLC
Value: combined offering price of $4.68
Effective: 2024-05-01

Exact text from the filing

On May 1, 2024, Aileron Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC, as underwriter (the “Underwriter”), relating to an underwritten offering (the “Offering”) of 4,273,505 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) and accompanying warrants (“Warrants”) to purchase 4,273,505 shares of Common Stock.

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Rein Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-127657

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.